BIIBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
BIOGEN INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 29, 2026
$233.48+0.83 (+0.36%)
Close on Oct 19, 2026
- Market cap
- $34.72B
- P/E (TTM)
- 41.3
- Dividend yield
- –
BIOGEN INC. revenue by segment
By business segment
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reportable Segment | $9.89B | $9.68B | $9.84B | $10.17B | – | – | – | – | – | – | 100.0% | +2.2% |
| Rest of world | – | – | – | – | – | – | – | – | $3.34B | $2.77B | – | – |
| U. S. [Member] | – | – | – | – | – | – | – | – | $7.02B | $7.05B | – | – |
By product or service
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Product revenue, net | $7.12B | $7.21B | $7.25B | $7.99B | $8.85B | $10.69B | $11.38B | $10.89B | $10.35B | $9.82B | 72.0% | -1.3% |
| MS Product Revenues | $4.04B | $4.35B | $4.66B | $5.43B | $6.10B | $7.83B | $8.53B | $8.60B | $8.98B | $8.82B | 40.8% | -7.1% |
| Rare Disease Product Revenue | $2.15B | $1.99B | $1.80B | $1.79B | $1.91B | – | – | – | – | – | 21.8% | +8.4% |
| Revenue from anti-CD20 therapeutic programs | $1.86B | $1.75B | $1.69B | $1.70B | $1.66B | – | – | – | – | – | 18.8% | +6.3% |
| TYSABRI | $1.67B | $1.72B | $1.88B | $2.03B | $2.06B | $1.95B | $1.89B | $1.86B | $1.97B | $1.96B | 16.8% | -2.9% |
| SPINRAZA | $1.55B | $1.57B | $1.74B | $1.79B | $1.91B | $2.05B | $2.10B | $1.72B | $883.70M | $4.60M | 15.6% | -1.7% |
| Fumarate | $1.43B | $1.60B | $1.59B | $2.00B | $2.36B | $3.91B | $4.44B | $4.27B | – | – | 14.4% | -10.6% |
| Royalty Attributed To OCREVUS | $1.41B | $1.34B | $1.27B | $1.14B | $991.70M | $845.40M | – | – | – | – | 14.3% | +5.6% |
| Interferon | $945.60M | $968.00M | $1.11B | $1.31B | $1.57B | $1.88B | $2.10B | $2.36B | $2.65B | $2.80B | 9.6% | -2.3% |
| VUMERITY | $746.80M | $628.00M | $576.30M | $553.40M | $410.40M | $64.30M | $5.50M | $0 | $0 | – | 7.6% | +18.9% |
| Contract manufacturing, royalty and other revenue | $732.90M | $652.60M | $899.30M | $485.10M | $476.30M | – | – | – | – | – | 7.4% | +12.3% |
| Biosimilars | $729.10M | $793.10M | $770.00M | $751.10M | $831.10M | $795.80M | $738.30M | $545.10M | $379.80M | $100.70M | 7.4% | -8.1% |
| AVONEX | $695.50M | $707.50M | $811.00M | $973.50M | $1.21B | $1.49B | – | – | $2.15B | $2.31B | 7.0% | -1.7% |
| TECFIDERA | $679.70M | $967.10M | $1.01B | $1.44B | $1.95B | $3.84B | – | – | – | – | 6.9% | -29.7% |
| Contract manufacturing revenue | $679.40M | $592.10M | $848.20M | $417.70M | $427.70M | $719.10M | – | – | – | – | 6.9% | +14.7% |
| SKYCLARYS | $520.50M | $382.50M | $55.90M | $0 | $0 | – | – | – | – | – | 5.3% | +36.1% |
| BENEPALI | $453.20M | $479.10M | $438.80M | $441.00M | $498.30M | $481.60M | $486.20M | $485.20M | $370.80M | $100.60M | 4.6% | -5.4% |
| PLEGRIDY | $250.10M | $260.50M | $294.70M | $331.90M | $357.40M | $385.60M | – | – | $494.30M | $481.70M | 2.5% | -4.0% |
| Other | $197.20M | $82.50M | $11.80M | $13.00M | $14.00M | – | – | – | – | – | 2.0% | +139.0% |
| ZURZUVAE | $195.10M | $72.20M | $1.60M | $0 | – | – | – | – | – | – | 2.0% | +170.2% |
| IMRALDI | $190.20M | $213.10M | $222.10M | $224.50M | $233.40M | $216.30M | $184.00M | $16.70M | $0 | $0 | 1.9% | -10.7% |
| Alzheimer's Collaboration | $177.70M | $59.90M | $0 | $0 | – | – | – | – | – | – | 1.8% | +196.7% |
| QALSODY | $86.90M | $32.40M | $5.90M | $0 | $0 | – | – | – | – | – | 0.9% | +168.2% |
| Royalty and other revenue | $53.50M | $60.50M | $51.10M | $67.40M | $48.60M | $55.50M | $17.00M | $38.70M | $69.80M | $46.50M | 0.5% | -11.6% |
| FLIXABI | $52.60M | $63.20M | $77.40M | $81.30M | $99.40M | $97.90M | $68.10M | $43.20M | $9.00M | $100.00K | 0.5% | -16.8% |
| BYOOVIZ | $32.40M | $36.60M | $31.70M | $4.30M | $0 | $0 | – | – | – | – | 0.3% | -11.5% |
| FUMADERM And ADUHELM | $2.10M | $10.30M | $10.20M | $13.00M | – | – | – | – | – | – | 0.0% | -79.6% |
| FAMPYRA | $1.40M | $71.70M | $90.50M | $96.60M | $105.20M | $103.10M | $97.10M | $92.70M | $91.60M | $84.90M | 0.0% | -98.0% |
| TOFIDENCE | $700.00K | $1.10M | $0 | $0 | – | – | – | – | – | – | 0.0% | -36.4% |
| TYSABRI | – | – | – | – | – | – | – | – | $1.97B | $1.96B | – | – |
| TECFIDERA | – | – | – | – | – | – | $4.43B | $4.27B | $4.21B | $3.97B | – | – |
| ALPROLIX | – | – | – | – | – | – | – | – | $26.00M | $333.70M | – | – |
| ELOCTATE | – | – | – | – | – | – | $0 | $0 | $48.40M | $513.20M | – | – |
| FUMADERM | – | – | – | $8.20M | $11.00M | $12.20M | $15.20M | $22.30M | $39.60M | $45.90M | – | – |
| ZINBRYTA | – | – | – | – | – | $0 | $0 | $1.40M | $52.70M | $7.80M | – | – |
| Hemophilia Products | – | – | – | – | – | – | $0 | $0 | $74.40M | $846.90M | – | – |
| ALPROLIX | – | – | – | – | – | – | $0 | $0 | $26.00M | $333.70M | – | – |
| Other corporate revenues | – | – | – | – | $427.70M | $719.10M | $584.50M | $459.40M | $253.70M | $230.60M | – | – |
| Revenue from anti-CD20 therapeutic programs | – | – | – | $1.70B | $1.66B | $1.98B | $2.29B | $1.98B | $1.56B | $1.31B | – | – |
| Contract manufacturing, royalty and other revenue | – | – | – | $485.10M | $476.30M | $774.60M | $707.70M | $585.90M | $360.00M | $316.40M | – | – |
| ADUHELM | – | – | – | $4.80M | $3.00M | $0 | $0 | – | – | – | – | – |
By region
| Revenue | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other | – | – | – | – | – | – | – | – | $332.70M | $313.00M | – | – |
| U. S. [Member] | – | – | – | – | – | – | – | – | $7.02B | $7.05B | – | – |
| Germany | – | – | – | – | – | – | – | – | – | $703.70M | – | – |
| Asia | – | – | – | – | – | – | – | – | $160.10M | $217.30M | – | – |
| Italy | – | – | – | – | – | – | – | – | – | $42.00M | – | – |
| Europe | – | – | – | – | – | – | – | – | $2.84B | $2.24B | – | – |
From the segment and revenue-disaggregation notes of Biogen's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.